blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3345917

EP3345917 - ANTIPROTOZOAL COMPOUNDS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.09.2022
Database last updated on 15.06.2024
FormerThe patent has been granted
Status updated on  18.10.2021
FormerGrant of patent is intended
Status updated on  23.02.2021
FormerExamination is in progress
Status updated on  19.06.2019
FormerRequest for examination was made
Status updated on  18.01.2019
FormerThe application has been published
Status updated on  08.06.2018
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR
published on 17.07.2024 [2024/29]
Applicant(s)For all designated states
Bacoba AG
Elisabethenstrasse 15
4051 Basel / CH
[2018/28]
Inventor(s)01 / Agnello, Stefano
Türgass 32
8820 Wädenswil / CH
02 / Adams, Michael
Weiherallee 7
8610 Uster / CH
03 / Kaiser, Marcel
Hauptstrasse 60
4324 Obermumpf / CH
04 / Mäser, Pascal
Therwilerstrasse 56
4153 Reinach / CH
05 / Urban, Alexander
Adamsgasse 13/14
1030 Wien / AT
06 / Raguz, Luka
Stettemerstrasse 163
8207 Schaffhausen / CH
07 / Riedl, Rainer
Hungerstrasse 46
8832 Wilen b. Wollerau / CH
 [2018/28]
Representative(s)Latscha Schöllhorn Partner AG
Grellingerstrasse 60
4052 Basel / CH
[2021/46]
Former [2018/28]Latscha Schöllhorn Partner AG
Austrasse 24
4051 Basel / CH
Application number, filing date17150353.505.01.2017
[2018/28]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3345917
Date:11.07.2018
Language:EN
[2018/28]
Type: B1 Patent specification 
No.:EP3345917
Date:17.11.2021
Language:EN
[2021/46]
Search report(s)(Supplementary) European search report - dispatched on:EP21.02.2017
ClassificationIPC:C07K7/02
[2018/28]
CPC:
C07K7/02 (EP); A61K38/00 (EP); Y02A50/30 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/08]
Former [2018/28]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Validation statesMA10.01.2019
TitleGerman:ANTIPROTOZOENVERBINDUNG[2018/28]
English:ANTIPROTOZOAL COMPOUNDS[2018/28]
French:COMPOSÉ ANTIPROTOZOAIRE[2018/28]
Examination procedure10.01.2019Amendment by applicant (claims and/or description)
10.01.2019Examination requested  [2019/08]
10.01.2019Date on which the examining division has become responsible
25.06.2019Despatch of a communication from the examining division (Time limit: M04)
30.01.2020Reply to a communication from the examining division
08.02.2021Cancellation of oral proceeding that was planned for 05.03.2021
24.02.2021Communication of intention to grant the patent
05.03.2021Date of oral proceedings (cancelled)
28.07.2021Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
06.10.2021Fee for grant paid
06.10.2021Fee for publishing/printing paid
06.10.2021Receipt of the translation of the claim(s)
Opposition(s)18.08.2022No opposition filed within time limit [2022/43]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
06.10.2021Request for further processing filed
06.10.2021Full payment received (date of receipt of payment)
Request granted
11.10.2021Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
30.01.2020Request for further processing filed
30.01.2020Full payment received (date of receipt of payment)
Request granted
11.02.2020Decision despatched
Fees paidRenewal fee
10.01.2019Renewal fee patent year 03
29.01.2020Renewal fee patent year 04
29.01.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.01.2017
AL17.11.2021
AT17.11.2021
CY17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
IT17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
MK17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
TR17.11.2021
IE05.01.2022
LU05.01.2022
BE31.01.2022
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
[2024/29]
Former [2024/22]HU05.01.2017
AL17.11.2021
AT17.11.2021
CY17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
IT17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
MK17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
IE05.01.2022
LU05.01.2022
BE31.01.2022
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2024/20]HU05.01.2017
AL17.11.2021
AT17.11.2021
CY17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
IT17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
IE05.01.2022
LU05.01.2022
BE31.01.2022
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2024/18]HU05.01.2017
AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
IT17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
IE05.01.2022
LU05.01.2022
BE31.01.2022
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2023/27]AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
IT17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
IE05.01.2022
LU05.01.2022
BE31.01.2022
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2023/09]AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
IE05.01.2022
LU05.01.2022
BE31.01.2022
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2023/01]AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
LU05.01.2022
BE31.01.2022
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/49]AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SK17.11.2021
SM17.11.2021
LU05.01.2022
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/46]AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SK17.11.2021
SM17.11.2021
LU05.01.2022
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/39]AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SK17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/35]AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SK17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/34]AT17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/33]AT17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RS17.11.2021
SE17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/25]AT17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RS17.11.2021
SE17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/24]AT17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RS17.11.2021
SE17.11.2021
BG17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/23]AT17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
PL17.11.2021
RS17.11.2021
BG17.02.2022
PT17.03.2022
Former [2022/22]AT17.11.2021
FI17.11.2021
LT17.11.2021
RS17.11.2021
BG17.02.2022
Former [2022/21]AT17.11.2021
RS17.11.2021
BG17.02.2022
Former [2022/19]BG17.02.2022
Documents cited:Search[XI]  - AKI ISHIYAMA ET AL, "In vitro and in vivo antitrypanosomal activities of three peptide antibiotics: leucinostatin A and B, alamethicin I and tsushimycin", THE JOURNAL OF ANTIBIOTICS, GB, (20090601), vol. 62, no. 6, doi:10.1038/ja.2009.32, ISSN 0021-8820, pages 303 - 308, XP055344637 [X] 1 * Abstract; Fig. 1 * [I] 2-15

DOI:   http://dx.doi.org/10.1038/ja.2009.32
 [XI]  - THOMAS DEGENKOLB ET AL, "Formation of New Lipoaminopeptides, Acremostatins A, B, and C, by Co-cultivation of Acremonium sp. Tbp-5 and Mycogone rosea DSM 12973", BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY., TOKYO, JAPAN, (20020122), vol. 66, no. 4, doi:10.1271/bbb.66.883, ISSN 0916-8451, pages 883 - 886, XP055344837 [X] 1 * Abstract; Fig. 1 * [I] 2-15

DOI:   http://dx.doi.org/10.1271/bbb.66.883
 [XI]  - ANA FLÁVIA CANOVAS MARTINEZ ET AL, "Liquid chromatography-tandem mass spectrometry characterization of five new leucinostatins produced by Paecilomyces lilacinus CG-189", THE JOURNAL OF ANTIBIOTICS, GB, (20150301), vol. 68, no. 3, doi:10.1038/ja.2014.120, ISSN 0021-8820, pages 178 - 184, XP055344838 [X] 1 * Abstract; Table 1. * [I] 2-15

DOI:   http://dx.doi.org/10.1038/ja.2014.120
 [XI]  - MICHAELA STACH ET AL, "Improved Strategy for the Synthesis of the Anticancer Agent Culicinin D", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, DE, (20151018), vol. 2015, no. 28, doi:10.1002/ejoc.201500872, ISSN 1434-193X, pages 6341 - 6350, XP055344854 [X] 1 * Abstract; Fig. 1 * [I] 2-15

DOI:   http://dx.doi.org/10.1002/ejoc.201500872
 [A]  - MARCEL KAISER ET AL, "Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning", PLOS ONE, (20150813), vol. 10, no. 8, doi:10.1371/journal.pone.0135556, page e0135556, XP055344644 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1371/journal.pone.0135556
 [XI]  - KAZUHIKO OTOGURO ET AL, "In Vitro Antimalarial Activities of the Microbial Metabolites.", THE JOURNAL OF ANTIBIOTICS, GB, (20030101), vol. 56, no. 3, doi:10.7164/antibiotics.56.322, ISSN 0021-8820, pages 322 - 324, XP055344799 [X] 1 * the whole document * [I] 2-15

DOI:   http://dx.doi.org/10.7164/antibiotics.56.322
by applicant   - SUNDAR S ET AL., CLIN. INFECT. DIS., vol. 31, no. 4, pages 1104 - 1107
    - THAKUR CP ET AL., J. MED. RES, vol. 120, no. 3, pages 166 - 172
    - THAKUR CP ET AL., TRANS. R. SOC. TROP. MED. HYG, vol. 93, no. 3, pages 319 - 323
    - THAKUR CP ET AL., TRANS. R. SOC. TROP. MED. HYG., vol. 90, no. 3, pages 319 - 322
    - SUNDAR S ET AL., CLIN. INFECT. DIS., vol. 42, no. 5, pages 608 - 613
    - VERTUANI ET AL., J. ANTIBIOTICS, (1995), vol. 48, no. 3, pages 254 - 260
    - ISOGAI ET AL., BIOSCI. BIOTECH BIOCHEM., (1992), vol. 56, no. 7, pages 1079 - 1085
    - OTOGORO ET AL., J. ANTIBIOTICS, (2003), vol. 3, pages 322 - 324
    - ISHIYAMA ET AL., J. ANTIBIOTICS, (2009), vol. 62, page 343
    - KHARE ET AL., NATURE, (2016), vol. 537, pages 229 - 233
    - K. KATSUNO ET AL., NATURE REVIEWS, (2015), vol. 14, pages 751 - 758
    - TETRAHEDRON LETTERS, (1991), vol. 32, pages 3985 - 3988
    - RAZ B ET AL., ACTA TROPICA, (1997), vol. 68, pages 139 - 147
    - BUCKNER FS ET AL., ANTIMICROB AGENTS CH1996, vol. 40, pages 2592 - 2597
    - BALTZ T ET AL., EMBO J, (1985), vol. 4, pages 1273 - 1277
    - TRAGER W.; JENSEN, J.B, SCIENCE, (1976), vol. 193, pages 673 - 675
    - YARDLEY V.; CROFT SL, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, (2000), vol. 13, pages 243 - 248
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.